Academic Interests

Dr. Zimmerman’s primary interest is the treatment of multiple myeloma and from this focus, he has developed expertise in stem cell transplantation, drug development and the treatment of cancer in elderly patients. With these interests, he and his colleagues have developed a comprehensive program for multiple myeloma in which many treatment options are made available to each patient on an individual basis. In addition, the program works closely with basic scientists in order to develop novel therapeutics for myeloma.

Clinical Interests

Multiple myeloma, stem cell transplantation

Representative Publications

  1. Zimmerman TM, Davis NB, Collins JC, VanBesien K. Phase I/II trial of high-dose melphalan with GM-CSF/IL-11 support preceding autologous or non-myeloablative allogeneic transplantation for patients with multiple myeloma. In preparation.
  2. Zimmerman TM,. Harlin H, Berk S, Stock W, Odenike O, Larson RL, Karrison T, Ratain MJ, Gajewski TM. Dose-ranging pharmacodynamic study or R115777 (tipifarnib) in patients with refractory and relapsed hematologic malignancies. In submission J Clin Oncol
  3. Odenike OM, Sobecks RM. Janich L, Huo D, Zimmerman T, Daugherty CK, Ratain MJ. Larson RL. Phase I trial of gemcitabine plus cladribine in patients with advanced hematological malignancies. In submission, Cancer Chem Pharmacol.
  4. Artz AS, VanBesien K, Zimmerman T, Gajewski TF, Rini BI, Hu HS, Stadler WM, Vogelzang NJ. Long-term follow up of non-myeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago experience. In submission, J Clin Oncol.
  5. Harlin H, Artz AS, Mahowald M, Rini BI, Zimmerman TM, Vogelzang NJ, Gajewski TM. Clinical responses following non-myelablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma producing T cells. In submission, Clin Can Res.

More Information

For more information about Dr. publications and research collaborations , please click here